UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/14.01.26 | Real-time BOERSE MUENCHEN 07:41:51 2024-06-26 EDT | ||
| 8.93 EUR | -1.98% |
|
| Current month | +44.60% | ||
| 1 month | +43.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 8.93 | -1.98% |
| 24-06-25 | 9.11 | +2.82% |
| 24-06-24 | 8.86 | +4.73% |
| 24-06-21 | 8.46 | +4.06% |
| 24-06-20 | 8.13 | -7.93% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 07:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD2FCM |
| ISIN | DE000HD2FCM3 |
| Date issued | 2024-02-05 |
| Strike | 1,100 $ |
| Maturity | 2026-01-14 (567 Days) |
| Parity | 10 : 1 |
| Emission price | 3.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.11 € |
|---|---|
| Lowest since issue | 3.25 € |
| Spread | 0.71 € |
| Spread % | 7.40% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
